AFM-15

N/A

Report date: 2026/03/19 16:57:35

Base Information

Drug NameAFM-15
Drug Alias Nameanti-CD3 humanized antibody (Affimed)human serum albumin antagonist (Affimed Therapeutics)AFM-15
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionSerum albumin antagonistsT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3Serum albumin
Therapy Area/IndicationsRejection of organ transplantationAutoimmune DiseasesDiabetes Mellitus, Type 1 +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAffimed Nv
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAffimed Nv
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationAutoimmune DiseasesDiabetes Mellitus, Type 1 +[6] 

Other Information

ATC CodeN/A
Related LinksN/A